Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. An industry perspective on CNS trauma (1)
4. An industry perspective on CNS trauma (2)
5. "Translation" to clinical research
6. Preclinical evidence wish list
7. The animal model problem
8. "Effective" treatments for experimental SCI
9. Against a small but significant counter-current
10. Animal SCI studies of "available" drugs
11. The regulatory path - a linear view
12. The regulatory path - realistic view
13. The challenge of development
14. Setting the primary endpoint bar in SCI
15. Reducing the noise
16. Where the light falls in acute SCI
17. What have we learned?
18. Outlook
19. Medical advance continues
20. In closing

Topics Covered

• The problems associated with developing therapies for acute spinal cord injury
• Need for reliable animal models
• Too many approaches appear to work
• Difficulties inherent in the clinical trial process
• The importance of establishing a clinically meaningful effect
• Defining useful primary endpoints

Links

Series:

• Neurotrauma

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Blight, A. (2011, October 27). Therapies for spinal cord injury: perspective from industry [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/HVUZ7925.
Export Citation (RIS)

Publication History

• Published on October 27, 2011

Financial Disclosures

• Dr. Andrew Blight, Full time employee and stockholder of Acroda Therapeutics, Inc.